{"id":1727,"date":"2006-05-01T12:04:00","date_gmt":"2006-05-01T10:04:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2006\/reversibles-posteriores-leukenzephalopathie-syndrom-nach-behandlung-mit-bevacizumab"},"modified":"2006-05-01T12:04:00","modified_gmt":"2006-05-01T10:04:00","slug":"reversibles-posteriores-leukenzephalopathie-syndrom-nach-behandlung-mit-bevacizumab","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2006\/reversibles-posteriores-leukenzephalopathie-syndrom-nach-behandlung-mit-bevacizumab","title":{"rendered":"Reversibles posteriores Leukenzephalopathie-Syndrom nach Behandlung mit Bevacizumab"},"content":{"rendered":"<p>H\u00e4ufige Symptome des reversiblen posterioren Leukenzephalopathie-Syndroms (RPLS) sind Kopfschmerzen, Bewusstseins- und Sehst\u00f6rungen sowie Kr\u00e4mpfe. Die Diagnose des RPLS beruht auf neuroradiologischen Untersuchungen mit Nachweis eines meistens symmetrisch auftretenden \u00d6dems in der wei\u00dfen Substanz der posterioren zerebralen Hemisph\u00e4ren, insbesondere parieto-okzipital, das mittels Computer-, besser aber mittels Magnetresonanz-Tomographie (MRT) erkennbar ist. Unterschiedliche Ursachen des RPLS, wie hypertensive [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>H\u00e4ufige Symptome des reversiblen posterioren Leukenzephalopathie-Syndroms (RPLS) sind Kopfschmerzen, Bewusstseins- und Sehst\u00f6rungen sowie Kr\u00e4mpfe. Die Diagnose des RPLS beruht auf neuroradiologischen Untersuchungen mit Nachweis eines meistens symmetrisch auftretenden \u00d6dems in der wei\u00dfen Substanz der posterioren zerebralen Hemisph\u00e4ren, insbesondere parieto-okzipital, das mittels Computer-, besser aber mittels Magnetresonanz-Tomographie (MRT) erkennbar ist. Unterschiedliche Ursachen des RPLS, wie hypertensive [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[2156,324,325,2217,1413],"class_list":["post-1727","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-bevacizumab","tag-blutdruck","tag-hypertonie","tag-progressive-multifokale-leukenzephalopathie","tag-sehstoerungen"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1727","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1727"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1727\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1727"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1727"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1727"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}